| Name | Title | Contact Details |
|---|
Oxyband Technologies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marina Biotech`s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company`s `next-generation of celecoxib,` including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103
Genome British Columbia is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases.
Acasti Pharma Inc. is an emerging biopharmaceutical company dedicated to the research, development and commercialization of innovative proprietary active pharmaceutical ingredients (API) for the management of cardiometabolic disorders, from prevention to treatment, through a novel superior approach to lipid regulation. To carry out this mission, Acasti is advancing its portfolio of bioactive ingredients, by purifying and concentrating krill-oil extracts through innovative technology, to produce products targeting the prescription drug and medical food markets.